NYSE:RCUS Arcus Biosciences Q3 2026 Earnings Report $24.43 -0.80 (-3.19%) Closing price 03:59 PM EasternExtended Trading$24.51 +0.08 (+0.34%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Arcus Biosciences EPS ResultsActual EPSN/AConsensus EPS -$0.88Beat/MissN/AOne Year Ago EPSN/AArcus Biosciences Revenue ResultsActual RevenueN/AExpected Revenue$11.14 millionBeat/MissN/AYoY Revenue GrowthN/AArcus Biosciences Announcement DetailsQuarterQ3 2026Date10/27/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Arcus Biosciences Earnings HeadlinesArcus Biosciences, Inc. Announces New Data for Casdatifan as Treatment for Kidney Cancer Across Multiple Lines of TherapySeptember 22, 2026 | marketscreener.comMArcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of TherapySeptember 22, 2026 | finance.yahoo.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.October 2 at 1:00 AM | American Hartford Gold (Ad)TD Cowen Initiates Arcus Biosciences at BuySeptember 16, 2026 | marketscreener.comMArcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comArcus Biosciences Announces New Employment Inducement GrantsSeptember 9, 2026 | businesswire.comSee More Arcus Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcus Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcus Biosciences and other key companies, straight to your email. Email Address About Arcus BiosciencesArcus Biosciences (NYSE:RCUS) is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation. Arcus’ oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist. These candidates are being evaluated in combination regimens and across multiple cancer types, including lung and gastrointestinal cancers. The company does not have a broad portfolio of marketed products and remains primarily focused on clinical-stage development. Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical development activities through collaborations and studies involving institutions and patients in the United States and other international markets. The company has maintained a strategic partnership with Gilead Sciences to advance and commercialize certain oncology programs. Arcus was co-founded and is led by Terry Rosen, Ph.D., who serves as chief executive officer.View Arcus Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
